vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and Porch Group, Inc. (PRCH). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $121.1M, roughly 1.5× Porch Group, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs -3.9%, a 17.2% gap on every dollar of revenue. On growth, Porch Group, Inc. posted the faster year-over-year revenue change (100.0% vs -1.8%). Over the past eight quarters, Porch Group, Inc.'s revenue compounded faster (26.4% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Porch is a website that tries to connect homeowners with local home improvement contractors. The site features advice articles, cost guide, and online booking for over 160 home projects.
AMPH vs PRCH — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $121.1M |
| Net Profit | $24.4M | $-4.7M |
| Gross Margin | 46.8% | 52.7% |
| Operating Margin | 19.4% | 34.7% |
| Net Margin | 13.3% | -3.9% |
| Revenue YoY | -1.8% | 100.0% |
| Net Profit YoY | -35.7% | 2.0% |
| EPS (diluted) | $0.51 | $-0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $121.1M | ||
| Q4 25 | $183.1M | $112.3M | ||
| Q3 25 | $191.8M | $115.1M | ||
| Q2 25 | $174.4M | $107.0M | ||
| Q1 25 | $170.5M | $84.5M | ||
| Q4 24 | $186.5M | $75.3M | ||
| Q3 24 | $191.2M | $77.7M | ||
| Q2 24 | $182.4M | $75.9M |
| Q1 26 | — | $-4.7M | ||
| Q4 25 | $24.4M | $-3.5M | ||
| Q3 25 | $17.4M | $-10.9M | ||
| Q2 25 | $31.0M | $2.6M | ||
| Q1 25 | $25.3M | $8.4M | ||
| Q4 24 | $38.0M | $30.5M | ||
| Q3 24 | $40.4M | $14.4M | ||
| Q2 24 | $37.9M | $-64.3M |
| Q1 26 | — | 52.7% | ||
| Q4 25 | 46.8% | 99.5% | ||
| Q3 25 | 51.4% | 75.6% | ||
| Q2 25 | 49.6% | 70.9% | ||
| Q1 25 | 50.0% | 77.4% | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | 79.4% | ||
| Q2 24 | 52.2% | 22.1% |
| Q1 26 | — | 34.7% | ||
| Q4 25 | 19.4% | 14.7% | ||
| Q3 25 | 13.2% | 14.2% | ||
| Q2 25 | 24.2% | 4.7% | ||
| Q1 25 | 21.9% | -1.5% | ||
| Q4 24 | 24.2% | 33.3% | ||
| Q3 24 | 29.8% | -3.2% | ||
| Q2 24 | 30.3% | -69.2% |
| Q1 26 | — | -3.9% | ||
| Q4 25 | 13.3% | -3.1% | ||
| Q3 25 | 9.0% | -9.4% | ||
| Q2 25 | 17.8% | 2.4% | ||
| Q1 25 | 14.8% | 9.9% | ||
| Q4 24 | 20.4% | 40.5% | ||
| Q3 24 | 21.1% | 18.5% | ||
| Q2 24 | 20.8% | -84.8% |
| Q1 26 | — | $-0.04 | ||
| Q4 25 | $0.51 | $0.00 | ||
| Q3 25 | $0.37 | $-0.10 | ||
| Q2 25 | $0.64 | $0.00 | ||
| Q1 25 | $0.51 | $0.07 | ||
| Q4 24 | $0.74 | $0.34 | ||
| Q3 24 | $0.78 | $0.12 | ||
| Q2 24 | $0.73 | $-0.65 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $68.4M |
| Total DebtLower is stronger | $608.7M | $391.3M |
| Stockholders' EquityBook value | $788.8M | $26.3M |
| Total Assets | $1.6B | $806.6M |
| Debt / EquityLower = less leverage | 0.77× | 14.87× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $68.4M | ||
| Q4 25 | $282.8M | $57.3M | ||
| Q3 25 | $276.2M | $85.0M | ||
| Q2 25 | $231.8M | $79.8M | ||
| Q1 25 | $236.9M | $70.4M | ||
| Q4 24 | $221.6M | $191.7M | ||
| Q3 24 | $250.5M | $238.6M | ||
| Q2 24 | $217.8M | $308.4M |
| Q1 26 | — | $391.3M | ||
| Q4 25 | $608.7M | $392.8M | ||
| Q3 25 | $608.6M | $387.1M | ||
| Q2 25 | $607.7M | $394.1M | ||
| Q1 25 | $603.9M | $409.2M | ||
| Q4 24 | $601.6M | $403.9M | ||
| Q3 24 | $596.4M | $399.0M | ||
| Q2 24 | $586.9M | $436.8M |
| Q1 26 | — | $26.3M | ||
| Q4 25 | $788.8M | $-24.6M | ||
| Q3 25 | $776.7M | $-27.9M | ||
| Q2 25 | $757.5M | $-29.3M | ||
| Q1 25 | $751.3M | $-52.4M | ||
| Q4 24 | $732.3M | $-43.2M | ||
| Q3 24 | $727.7M | $-77.0M | ||
| Q2 24 | $713.3M | $-101.9M |
| Q1 26 | — | $806.6M | ||
| Q4 25 | $1.6B | $797.4M | ||
| Q3 25 | $1.7B | $787.7M | ||
| Q2 25 | $1.6B | $770.7M | ||
| Q1 25 | $1.6B | $802.3M | ||
| Q4 24 | $1.6B | $814.0M | ||
| Q3 24 | $1.5B | $867.3M | ||
| Q2 24 | $1.5B | $876.1M |
| Q1 26 | — | 14.87× | ||
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | — |
| Free Cash FlowOCF − Capex | $24.6M | — |
| FCF MarginFCF / Revenue | 13.4% | — |
| Capex IntensityCapex / Revenue | 4.5% | — |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $32.9M | $1.2M | ||
| Q3 25 | $52.6M | $40.8M | ||
| Q2 25 | $35.6M | $35.6M | ||
| Q1 25 | $35.1M | $-11.2M | ||
| Q4 24 | $29.0M | $-26.6M | ||
| Q3 24 | $60.0M | $12.4M | ||
| Q2 24 | $69.1M | $-26.0M |
| Q1 26 | — | — | ||
| Q4 25 | $24.6M | $1.1M | ||
| Q3 25 | $47.2M | $40.7M | ||
| Q2 25 | $25.0M | $35.4M | ||
| Q1 25 | $24.4M | $-11.2M | ||
| Q4 24 | $16.6M | $-26.8M | ||
| Q3 24 | $46.2M | $12.2M | ||
| Q2 24 | $63.1M | $-26.0M |
| Q1 26 | — | — | ||
| Q4 25 | 13.4% | 1.0% | ||
| Q3 25 | 24.6% | 35.4% | ||
| Q2 25 | 14.3% | 33.0% | ||
| Q1 25 | 14.3% | -13.3% | ||
| Q4 24 | 8.9% | -35.6% | ||
| Q3 24 | 24.1% | 15.7% | ||
| Q2 24 | 34.6% | -34.3% |
| Q1 26 | — | — | ||
| Q4 25 | 4.5% | 0.1% | ||
| Q3 25 | 2.8% | 0.1% | ||
| Q2 25 | 6.1% | 0.2% | ||
| Q1 25 | 6.3% | 0.1% | ||
| Q4 24 | 6.7% | 0.3% | ||
| Q3 24 | 7.2% | 0.3% | ||
| Q2 24 | 3.3% | 0.1% |
| Q1 26 | — | — | ||
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | 13.79× | ||
| Q1 25 | 1.39× | -1.33× | ||
| Q4 24 | 0.76× | -0.87× | ||
| Q3 24 | 1.48× | 0.86× | ||
| Q2 24 | 1.82× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
PRCH
Segment breakdown not available.
